A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin
Crossref DOI link:
Published Online: 2017-11-06
Published Print: 2017-12
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
O’Neill, Edward A.
Kaufman, Keith D.
Engel, Samuel S.
Funding for this research was provided by: